In a rapidly changing world, the best businesses are not merely efficient today—they are capable of learning, adapting and becoming stronger when conditions change. For AXISCADES - Shift from services to IP and platforms - Expansion into ESAI and system-level solutions - Exit from non-core, loss-making businesses - Major investment in defence, aerospace and strategic electronics - Creation of new technology infrastructure

Good one to bookmark. Top Effort/thinking on collating this one

theverge.com/news/1002563/ap… AXISCADES can potentially participate in stages C and D, and possibly parts of hardware/firmware development through Mistral’s chip-to-product capability. AXISCADES disclosed two related hyperscaler engagements:

Interesting nugget from Deep Industries’ Bharat Connect discussion 👀 Got clarity on Deep’s competition in Production Enhancement Contracts (PECs): • RBM Infracon – infra/EPC player entering PEC • BVishal Oil & Energy – Mehsana-based oilfield specialist already executing PECs What stands out for Deep is its integrated stack — drilling + workover + compression + processing + IPM, all capabilities required to enhance production. If Deep wins another PEC, PEC #1 proves capability; PEC #2 could prove repeatability. That’s when this vertical gets really interesting.

ACE’s gross defence order pool is now ~₹592 crore; the exact unexecuted backlog will be known only after Q2 results/call. It is a strong confirmation that ACE’s backhoe-loader entry is gaining acceptance and that the defence pipeline is broadening beyond the original ₹575 crore backlog. - Management expected a possible ₹100 crore-plus repeat defence order in the next 2–3 quarters - This order fits the guided pipeline, although the exact order was not named. They can do 560-600Cr PAT with the defense angle rerating them. And Price hike they have taken too. Fy28 850Cr Fy29 1100Cr possible. D: Do ur own due diligence pls. Just sharing information which could help. Source : @tenderdekho Website.

Uflex Q1 was largely a price/spread-led quarter, but the September update suggests the setup continued into Q2. BOPET/BOPP spreads reportedly improved further through August–September, while Americas and Middle East/Africa demand remains supported by local sourcing amid freight and supply-chain disruption. The important caveat is that total Q1 volume growth was only 1.7%, and aseptic faced Indonesian duty-free import pressure. Egypt aseptic also looks like an H2 catalyst now, rather than a Q2 contributor. For a rerating, Q2 needs to show normalised EBITDA margin holding above 14%, film volumes improving, PET-chip realisations strengthening and debt reduction continuing. Bottom Line: Two strong quarters would make the FY27 earnings reset and lower-leverage story far more credible. gautamchopra.substack.com/p/…

AXISCADES is no longer a straightforward defence/ER&D company. It is trying to sell mature engineering-services assets at a high valuation, use the proceeds to reduce debt and buy/build higher-barrier manufacturing capability in defence, aerospace, semiconductor/AI hardware and space. Buy the FY28 inflection, not the FY30 dream. The most important proof points over the next 6–12 months are divestment cash, debt reduction, DSO/operating cash flow, and whether the aerospace acquisition begins contributing as promised. The Abakkus deal: positive signal, but interpret it correctly Abakkus bought about 12.88 lakh shares (3.03%), while Kotak AMC also participated in the block deal. That is a meaningful institutional validation of the transformed-business thesis

Six Dots. Five ANDs: A Framework for Trimming Winners Trimming or selling a winner is an exercise in judgement. Never confuse attachment to a stock with conviction in the thesis. #Sansera Engineering antifragilethinking.substack…

Aarti Pharmalabs combines a strong xanthine cash engine with regulated APIs and an expanding CDMO platform. The next phase depends on converting new capacity—especially Atali—into qualified, repeat commercial revenues. Long form : How a xanthine cash engine, regulated APIs and Atali’s CDMO scale-up could reshape the business. gautamchopra.substack.com/p/…

HDFC Securities models US humanoid shipments going from 30,000 in CY27 to 15.6 million by CY35. A 500x jump in volume. Now the price. $30,000 per robot in 2027. $26,900 in 2035. Just a 13% drop in 9 years. Every hardware boom so far has crushed prices as volumes rose. This one is modelled to hold them. That's the assumption to watch. The homework happens now, not when the trend is on every screen. Who's building the robots. Who supplies the parts inside them - actuators, gears, sensors, precision metal components. Which listed companies, including in India, sit anywhere on that chain, and what the market is paying for them today. When the trend starts playing out, you want to already have that list. Stay not out

#HFCL - Bharat Connect Conference – HFCL significantly raised its growth outlook, with management highlighting: • FY27 revenue growth guidance raised from 40% to a minimum of 60% YoY, with management confident that strong growth can continue beyond FY27 • ₹28,000 Cr order book, including ₹19,000 Cr from optical fiber cables and data center interconnects, providing strong revenue visibility • Optical fiber capacity to expand from 28M to 43M fiber km and cable capacity from 39M to 62M fiber km by July 2028 • ₹2,500 Cr CapEx planned over the next 2.5 years, including ₹1,250 Cr for a new preform facility that can improve product margins by up to 5% at full integration • Defense revenue targeted at ₹500 Cr this year, ₹1,500 Cr next year and ₹4,000–5,000 Cr by FY30, supported by a ₹2,050 Cr aerospace order book • AI and data center hyperscalers already contribute 85–90% of revenue, with higher-margin interconnect solutions and fiber products driving the current growth cycle Key guidance, growth drivers and management commentary below 👇 Disclaimer: This post is for informational purposes only and is not investment advice or a recommendation to buy or sell.

That is a very sharp framework. In niche manufacturing, the first re-rating rarely waits for a full P&L transformation. It begins when the market recognises that the company has crossed a threshold that cannot be replicated by capex alone: specialised equipment, process learning, certification, customer qualification and failure-critical products. NRB and Sunflag capture the two ends of this journey. NRB • Market is pricing: aerospace access, AS9100D certification, precision-engineering capability and bearing optionality. • Must prove: initial orders convert into repeat, platform-level aerospace revenue. Sunflag • Market is pricing: VIM/VAR/ESR capability, aerospace approvals and superalloy optionality. • Must prove: commercial alloy volumes, mix shift and sustained margin improvement. Capability earns attention. Qualification earns the premium. Execution decides whether it lasts.

Good for players like VOEPL

US pharma tariff relief — key takeaway India is on the U.S. zero-tariff list for specific high-value pharma categories: orphan/rare-disease drugs, fertility treatments, cell & gene therapies, ADCs and animal-health products. This is not a blanket benefit for Indian pharma: generics and biosimilars were already outside the new 100% tariff; benefit is product-specific. Shilpa Medicare is the cleanest thematic beneficiary via ADC / bioconjugation and biologics CDMO capabilities. Zydus has interesting optionality through rare-disease innovation and animal-health exposure. DRL has rare-disease / biologics optionality, but likely longer dated. Sun Pharma benefits as specialty-risk protection, though exact eligible US products need confirmation. Cipla, Biocon and Hester are more indirect / speculative links—not immediate earnings calls. The broader positive: it improves India’s competitiveness as a specialty API, biologics and ADC manufacturing base for US customers.

Second that. Completely agree. The Supreme Court’s refusal to stay the MDR only allows the framework to begin—it does not make the economics investable yet. Until there is clarity on the revenue pool, its split across banks/NPCI/TPAPs, merchant absorption versus pass-through, and the final legal outcome, it is difficult to underwrite a durable revenue or PAT stream. Better to watch the policy settle than build a thesis around a government-determined take rate.

Axiscades - block deal pretty high Px i guess Stock itself is Up 10% in pre mkt Will review once it settles

Sales! Not expecting huge discounts at all + the website breaking when you actually find a good deal

Quality Power's AGM solidifies a corporate transition from a domestic component maker into a global high-voltage transmission platform. - KPI should be timely conversion of the 1,945 Cr order book and the smooth commissioning of the 8x Sangli expansion - Promoters waiving dividends conserves cash for capex, rewarding non-promoters; peers like BCL Industries, Syncom Formulations, and Elitecon have executed identical waivers. (promoter group—holding a 73.91%) Pointing out if someone didn't notice the waive. Non promoter receives cash yields without bleeding corp liquidity.

🎙️ DEE Development Engineers (DEEDEV) call was streaming live on EquiSense, it just ended. Here is the decode ⬇️ DEE is executing an asset-sweating strategy where existing 740 Cr gross block supports the runway toward 2,500 Cr topline by FY29 without heavy fresh capex. The core tension sits between massive order visibility (2,400 Cr order book plus 1,000 Cr H2 inflows) and execution pacing constrained by skilled labor availability and customer drawing clearances as Anjar utilization scales from 40-50% toward 70%. Growth triggers • Q3 FY27: External seamless pipe billing go-live: first commercial third-party shipments commence in Q3 FY27, unlocking high-margin domestic boiler integral piping demand. • Q3 FY27: Siemens qualification audit: the vendor audit of the Anjar facility scheduled for October 6-8, 2026 unlocks balance of plant and auxiliary piping tenders for global gas turbine programs. • FY28: Siemens and GE export execution ramp: international gas turbine piping orders for Siemens and GE convert into revenue streams starting FY28, with Siemens order potential matching or exceeding GE volumes. Full call, decoded: equisense.ai/app/deep-dive.h… #DEEDEV #InvestorCall #GuidanceMaintained #OptimisticTone #HighTransparency #GrowthStory

I’m excited to announce my partnership with OpenAI. We have some interesting things coming up, and I can’t wait to share them with you. I’ve always been curious... One question usually leads to another, and ChatGPT has certainly encouraged that habit. But it has also proved useful when I’ve needed to get things done, like planning my last trip with the family. That’s what I’m looking forward to with this partnership. Discovering what else I can do with ChatGPT, sharing what I find useful, and encouraging more people to give it a try with something they care about. A question, an idea, something you’ve always wanted to explore. There are so many places to start. Looking forward to exploring together. #Partnership